OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Nonalcoholic fatty liver disease: lifestyle and quality of life
Ilias D. Vachliotis, A. Goulas, Paraskevi Papaioannidou, et al.
HORMONES (2021) Vol. 21, Iss. 1, pp. 41-49
Closed Access | Times Cited: 41
Ilias D. Vachliotis, A. Goulas, Paraskevi Papaioannidou, et al.
HORMONES (2021) Vol. 21, Iss. 1, pp. 41-49
Closed Access | Times Cited: 41
Showing 1-25 of 41 citing articles:
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 191
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 191
Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy
Stergios A. Pοlyzos, Lampros Chrysavgis, Ilias D. Vachliotis, et al.
Seminars in Cancer Biology (2023) Vol. 93, pp. 20-35
Closed Access | Times Cited: 45
Stergios A. Pοlyzos, Lampros Chrysavgis, Ilias D. Vachliotis, et al.
Seminars in Cancer Biology (2023) Vol. 93, pp. 20-35
Closed Access | Times Cited: 45
Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease
Stergios A. Pοlyzos, Ilias D. Vachliotis, Christos S. Mantzoros
Metabolism (2023) Vol. 147, pp. 155676-155676
Closed Access | Times Cited: 33
Stergios A. Pοlyzos, Ilias D. Vachliotis, Christos S. Mantzoros
Metabolism (2023) Vol. 147, pp. 155676-155676
Closed Access | Times Cited: 33
Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease
Dimitrios D. Raptis, Christos S. Mantzoros, Stergios A. Pοlyzos
Therapeutics and Clinical Risk Management (2023) Vol. Volume 19, pp. 77-96
Open Access | Times Cited: 22
Dimitrios D. Raptis, Christos S. Mantzoros, Stergios A. Pοlyzos
Therapeutics and Clinical Risk Management (2023) Vol. Volume 19, pp. 77-96
Open Access | Times Cited: 22
Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis
Eun Joo Lee, Miyoung Choi, Sang Bong Ahn, et al.
World Journal of Pediatrics (2024) Vol. 20, Iss. 6, pp. 569-580
Closed Access | Times Cited: 10
Eun Joo Lee, Miyoung Choi, Sang Bong Ahn, et al.
World Journal of Pediatrics (2024) Vol. 20, Iss. 6, pp. 569-580
Closed Access | Times Cited: 10
Combination Therapies for Nonalcoholic Fatty Liver Disease
Evangelia Makri, Eleftheria Makri, Stergios A. Pοlyzos
Journal of Personalized Medicine (2022) Vol. 12, Iss. 7, pp. 1166-1166
Open Access | Times Cited: 36
Evangelia Makri, Eleftheria Makri, Stergios A. Pοlyzos
Journal of Personalized Medicine (2022) Vol. 12, Iss. 7, pp. 1166-1166
Open Access | Times Cited: 36
Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease
Stergios A. Pοlyzos, Dimitrios G. Goulis, Όλγα Γιουλεμέ, et al.
Current Obesity Reports (2022) Vol. 11, Iss. 3, pp. 166-179
Closed Access | Times Cited: 29
Stergios A. Pοlyzos, Dimitrios G. Goulis, Όλγα Γιουλεμέ, et al.
Current Obesity Reports (2022) Vol. 11, Iss. 3, pp. 166-179
Closed Access | Times Cited: 29
The Role of CTGF in Liver Fibrosis Induced in 3D Human Liver Spheroids
Sara Redenšek, Sander van Riet, Åsa Nordling, et al.
Cells (2023) Vol. 12, Iss. 2, pp. 302-302
Open Access | Times Cited: 16
Sara Redenšek, Sander van Riet, Åsa Nordling, et al.
Cells (2023) Vol. 12, Iss. 2, pp. 302-302
Open Access | Times Cited: 16
Borneol Ameliorates Non‐Alcoholic Fatty Liver Disease via Promoting AMPK‐Mediated Lipophagy
Shalemraju Sriramdasu, Shivam Sharma, Abid Reza Ansari, et al.
Journal of Biochemical and Molecular Toxicology (2025) Vol. 39, Iss. 2
Closed Access
Shalemraju Sriramdasu, Shivam Sharma, Abid Reza Ansari, et al.
Journal of Biochemical and Molecular Toxicology (2025) Vol. 39, Iss. 2
Closed Access
Deciphering the role of Dietary Modifications and Gut Dysbiosis in Non-Alcoholic Fatty Liver Disease
Meenakshi Vachher, Kamaljeet Kaur, Manisha Mahrotra, et al.
Human Nutrition & Metabolism (2025), pp. 200305-200305
Open Access
Meenakshi Vachher, Kamaljeet Kaur, Manisha Mahrotra, et al.
Human Nutrition & Metabolism (2025), pp. 200305-200305
Open Access
Tactics with Prebiotics for the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease via the Improvement of Mitophagy
Ai Tsuji, Sayuri Yoshikawa, Yuka Ikeda, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5465-5465
Open Access | Times Cited: 15
Ai Tsuji, Sayuri Yoshikawa, Yuka Ikeda, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5465-5465
Open Access | Times Cited: 15
Digital Therapeutics: Emerging New Therapy for Nonalcoholic Fatty Liver Disease
Run Zhou, Yunpeng Gu, Binbin Zhang, et al.
Clinical and Translational Gastroenterology (2023)
Open Access | Times Cited: 12
Run Zhou, Yunpeng Gu, Binbin Zhang, et al.
Clinical and Translational Gastroenterology (2023)
Open Access | Times Cited: 12
The interactive effects of psychosocial stress and diet composition on health in primates
Carol A. Shively, Brett M. Frye, Jacob D. Negrey, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 152, pp. 105320-105320
Open Access | Times Cited: 12
Carol A. Shively, Brett M. Frye, Jacob D. Negrey, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 152, pp. 105320-105320
Open Access | Times Cited: 12
Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives
Janitha M. Unagolla, Subarna Das, Riley Flanagan, et al.
International Journal of Pharmaceutics (2024) Vol. 660, pp. 124381-124381
Closed Access | Times Cited: 4
Janitha M. Unagolla, Subarna Das, Riley Flanagan, et al.
International Journal of Pharmaceutics (2024) Vol. 660, pp. 124381-124381
Closed Access | Times Cited: 4
Hepatic steatosis induced by nicotine plus Coca-Cola™ is prevented by nicotinamide riboside (NR)
Juan Carlos H Hernández-Rivera, Jorge Espinoza‐Derout, Kamrul M. Hasan, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 3
Juan Carlos H Hernández-Rivera, Jorge Espinoza‐Derout, Kamrul M. Hasan, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 3
Hypogonadism and nonalcoholic fatty liver disease
Kasiani Papadimitriou, Athanasios Mousiolis, Gesthimani Mintziori, et al.
Endocrine (2024) Vol. 86, Iss. 1, pp. 28-47
Closed Access | Times Cited: 3
Kasiani Papadimitriou, Athanasios Mousiolis, Gesthimani Mintziori, et al.
Endocrine (2024) Vol. 86, Iss. 1, pp. 28-47
Closed Access | Times Cited: 3
Gut Microbes, Diet, and Genetics as Drivers of Metabolic Liver Disease: A Narrative Review Outlining Implications for Precision Medicine
Jake B. Hermanson, Samar A. Tolba, Evan A. Chrisler, et al.
The Journal of Nutritional Biochemistry (2024) Vol. 133, pp. 109704-109704
Closed Access | Times Cited: 3
Jake B. Hermanson, Samar A. Tolba, Evan A. Chrisler, et al.
The Journal of Nutritional Biochemistry (2024) Vol. 133, pp. 109704-109704
Closed Access | Times Cited: 3
Impact of rumination on sleep quality among patients with non‑alcoholic fatty liver disease: a moderated mediation model of anxiety symptoms and resilience
Xiaolin Chang, Chenxi Guo, Zhou Heng, et al.
BMC Psychiatry (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Xiaolin Chang, Chenxi Guo, Zhou Heng, et al.
BMC Psychiatry (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Non-alcoholic Fatty Liver Disease in Children
Emir Muzurović, Stergios A. Pοlyzos, Dimitri P. Mikhailidis, et al.
Current Vascular Pharmacology (2022) Vol. 21, Iss. 1, pp. 4-25
Closed Access | Times Cited: 15
Emir Muzurović, Stergios A. Pοlyzos, Dimitri P. Mikhailidis, et al.
Current Vascular Pharmacology (2022) Vol. 21, Iss. 1, pp. 4-25
Closed Access | Times Cited: 15
Partial validation of a six-month high-fat diet and fructose-glucose drink combination as a mouse model of nonalcoholic fatty liver disease
Evangelia Makri, Konstantinos Xanthopoulos, Panagiotis Mavrommatis-Parasidis, et al.
Endocrine (2024) Vol. 85, Iss. 2, pp. 704-716
Open Access | Times Cited: 2
Evangelia Makri, Konstantinos Xanthopoulos, Panagiotis Mavrommatis-Parasidis, et al.
Endocrine (2024) Vol. 85, Iss. 2, pp. 704-716
Open Access | Times Cited: 2
Animal studies on glucagon-like peptide-1 receptor agonists and related polyagonists in nonalcoholic fatty liver disease
Chara Tsiampali, Ilias D. Vachliotis, A. Goulas, et al.
HORMONES (2024) Vol. 23, Iss. 4, pp. 611-619
Open Access | Times Cited: 2
Chara Tsiampali, Ilias D. Vachliotis, A. Goulas, et al.
HORMONES (2024) Vol. 23, Iss. 4, pp. 611-619
Open Access | Times Cited: 2
Grape seed extract supplementation in non-alcoholic fatty liver disease
Parisa Ghanbari, Roghayeh Alboebadi, Hadi Bazyar, et al.
International Journal for Vitamin and Nutrition Research (2024) Vol. 94, Iss. 5-6, pp. 365-376
Closed Access | Times Cited: 1
Parisa Ghanbari, Roghayeh Alboebadi, Hadi Bazyar, et al.
International Journal for Vitamin and Nutrition Research (2024) Vol. 94, Iss. 5-6, pp. 365-376
Closed Access | Times Cited: 1
Drosophila melanogaster as a Biotechnological Tool to Investigate the Close Connection Between Fatty Diseases and Pesticides
Fabiano Cláudio de Oliveira-Júnior, Ana Caroline Pimentel de Oliveira, Camila Cristiane Pansa, et al.
Brazilian Archives of Biology and Technology (2024) Vol. 67
Open Access | Times Cited: 1
Fabiano Cláudio de Oliveira-Júnior, Ana Caroline Pimentel de Oliveira, Camila Cristiane Pansa, et al.
Brazilian Archives of Biology and Technology (2024) Vol. 67
Open Access | Times Cited: 1
Hepatic thyroid hormone receptor‐β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction‐associated steatohepatitis
Stergios A. Pοlyzos, Giovanni Targher
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 1
Stergios A. Pοlyzos, Giovanni Targher
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 1
Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient‐reported quality of life
Laura Heath, Paul Aveyard, Jeremy Tomlinson, et al.
Hepatology Communications (2022) Vol. 6, Iss. 10, pp. 2623-2633
Open Access | Times Cited: 6
Laura Heath, Paul Aveyard, Jeremy Tomlinson, et al.
Hepatology Communications (2022) Vol. 6, Iss. 10, pp. 2623-2633
Open Access | Times Cited: 6
